[go: up one dir, main page]

DK1756064T3 - Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder - Google Patents

Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder

Info

Publication number
DK1756064T3
DK1756064T3 DK05754758T DK05754758T DK1756064T3 DK 1756064 T3 DK1756064 T3 DK 1756064T3 DK 05754758 T DK05754758 T DK 05754758T DK 05754758 T DK05754758 T DK 05754758T DK 1756064 T3 DK1756064 T3 DK 1756064T3
Authority
DK
Denmark
Prior art keywords
compounds
methods
compositions containing
pyrazole derivatives
pyrazole
Prior art date
Application number
DK05754758T
Other languages
English (en)
Inventor
Emma R Parmee
Yusheng Xiong
Jian Guo
Rui Liang
Linda Brockunier
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK1756064T3 publication Critical patent/DK1756064T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK05754758T 2004-06-04 2005-05-31 Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder DK1756064T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04
PCT/US2005/018828 WO2005121097A2 (en) 2004-06-04 2005-05-31 Pyrazole derivatives, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
DK1756064T3 true DK1756064T3 (da) 2008-09-22

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05754758T DK1756064T3 (da) 2004-06-04 2005-05-31 Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder

Country Status (34)

Country Link
US (2) US7598285B2 (da)
EP (1) EP1756064B1 (da)
JP (2) JP4108739B2 (da)
CN (1) CN1964947A (da)
AR (2) AR049291A1 (da)
AT (1) ATE395338T1 (da)
AU (2) AU2005252183B2 (da)
BR (1) BRPI0511703B8 (da)
CA (1) CA2566945C (da)
CR (1) CR8766A (da)
CY (1) CY1108544T1 (da)
DE (1) DE602005006806D1 (da)
DK (1) DK1756064T3 (da)
EA (1) EA012431B1 (da)
EC (1) ECSP067062A (da)
ES (1) ES2306165T3 (da)
GE (1) GEP20094605B (da)
HR (1) HRP20080311T3 (da)
IL (1) IL179754A (da)
MA (1) MA28673B1 (da)
MX (1) MXPA06014084A (da)
MY (1) MY143599A (da)
NI (1) NI200600290A (da)
NO (1) NO339149B1 (da)
NZ (1) NZ551405A (da)
PE (1) PE20060427A1 (da)
PL (1) PL1756064T3 (da)
PT (1) PT1756064E (da)
SI (1) SI1756064T1 (da)
TN (1) TNSN06397A1 (da)
TW (1) TWI293952B (da)
UA (1) UA85884C2 (da)
WO (1) WO2005121097A2 (da)
ZA (1) ZA200609489B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
JP2008507528A (ja) * 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
EP1910303A2 (en) 2005-07-26 2008-04-16 Merck & Co., Inc. Process for synthesizing a substituted pyrazole
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2008087029A1 (en) * 2007-01-17 2008-07-24 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2170337A4 (en) * 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
CA2717138A1 (en) 2008-03-05 2009-09-11 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes
AU2009224418B2 (en) 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
WO2009140342A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010039789A1 (en) * 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
JP5694561B2 (ja) 2010-12-23 2015-04-01 ファイザー・インク グルカゴン受容体モジュレーター
KR101638671B1 (ko) 2011-02-08 2016-07-11 화이자 인코포레이티드 글루카곤 수용체 조절자
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN118236497A (zh) 2016-08-30 2024-06-25 瑞泽恩制药公司 通过干扰胰高血糖素受体的信号传导治疗重度胰岛素抵抗的方法
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
CA3071387A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
EP3752249A1 (en) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Glucagon receptor antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0948257A4 (en) 1996-11-20 1999-12-29 Merck & Co Inc TRIARYL-SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING THE SAME AND METHOD FOR THEIR USE
AU726311B2 (en) 1996-11-20 2000-11-02 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
AU730295B2 (en) 1996-11-20 2001-03-01 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
WO1998025907A1 (en) * 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
NZ500141A (en) 1997-04-18 2002-05-31 G Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DK1042293T3 (da) 1997-12-19 2008-07-14 Amgen Inc Substituerede pyridin- og pyridazinforbindelser og deres farmaceutiske anvendelse
DE69939481D1 (de) 1998-09-17 2008-10-16 Bristol Myers Squibb Co Methode zur behandlung von diabetes die einen ap2-inhibitor und dazugehörige kombinationen verwendet
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
AU5841400A (en) * 1999-08-10 2001-03-05 Nihon Bayer Agrochem K.K. Herbicidal tetrazolinone derivatives
IL149493A0 (en) * 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2002008188A1 (en) * 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
CA2473591C (en) * 2002-02-01 2011-11-01 Dainippon Pharmaceutical Co., Ltd. 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
MXPA05000816A (es) 2002-07-19 2005-04-28 Baxter Int Sistemas y metodos para realizar dialisis peritoneal.
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
AU2003298889A1 (en) * 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
WO2004069158A2 (en) * 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2522080A1 (en) * 2003-04-14 2004-10-28 The Institutes For Pharmaceutical Discovery, Llc N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
WO2004100875A2 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
ES2306165T3 (es) 2004-06-04 2008-11-01 MERCK & CO., INC. Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso.
JP2008507528A (ja) * 2004-07-22 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 置換ピラゾール、このような化合物を含有する組成物及び使用方法
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
PE20060427A1 (es) 2006-06-19
EP1756064B1 (en) 2008-05-14
UA85884C2 (uk) 2009-03-10
IL179754A0 (en) 2007-05-15
NZ551405A (en) 2009-06-26
CN1964947A (zh) 2007-05-16
MA28673B1 (fr) 2007-06-01
AU2008229701C1 (en) 2010-07-29
DE602005006806D1 (de) 2008-06-26
HRP20080311T3 (hr) 2008-07-31
TNSN06397A1 (en) 2008-02-22
ZA200609489B (en) 2007-10-31
CA2566945C (en) 2010-09-21
TWI293952B (en) 2008-03-01
US20090176854A1 (en) 2009-07-09
TW200604179A (en) 2006-02-01
PL1756064T3 (pl) 2008-11-28
BRPI0511703B8 (pt) 2021-05-25
EP1756064A2 (en) 2007-02-28
EA200602196A1 (ru) 2007-06-29
BRPI0511703A (pt) 2008-01-08
GEP20094605B (en) 2009-02-10
PT1756064E (pt) 2008-07-22
JP2008505062A (ja) 2008-02-21
AU2005252183B2 (en) 2008-07-17
AU2005252183A1 (en) 2005-12-22
SI1756064T1 (sl) 2008-12-31
EA012431B1 (ru) 2009-10-30
JP4733153B2 (ja) 2011-07-27
ATE395338T1 (de) 2008-05-15
WO2005121097A3 (en) 2006-02-16
IL179754A (en) 2013-12-31
NI200600290A (es) 2007-08-07
US7799818B2 (en) 2010-09-21
AR049291A1 (es) 2006-07-12
ECSP067062A (es) 2007-01-26
JP4108739B2 (ja) 2008-06-25
ES2306165T3 (es) 2008-11-01
NO339149B1 (no) 2016-11-14
JP2008150388A (ja) 2008-07-03
WO2005121097A2 (en) 2005-12-22
AR088919A2 (es) 2014-07-16
NO20070073L (no) 2007-03-05
AU2008229701B2 (en) 2010-03-04
MY143599A (en) 2011-06-15
AU2008229701A1 (en) 2008-10-30
US20050272794A1 (en) 2005-12-08
US7598285B2 (en) 2009-10-06
BRPI0511703B1 (pt) 2018-07-17
CA2566945A1 (en) 2005-12-22
MXPA06014084A (es) 2007-02-15
CR8766A (es) 2007-08-28
CY1108544T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
DK1756064T3 (da) Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
DK1758914T3 (da) Hidtil ukendte fluorglycosidderivater af pyrazoler, lægemidler indeholdende disse forbindelser og anvendelse heraf
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
IS7966A (is) Pyrazól og aðferðir við að búa þau til og notkun þeirra
DK3305776T3 (da) Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
DK1532145T3 (da) Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3
ATE370142T1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DK1648426T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
NO20081604L (no) Nitrogeninneholdende heterocyklisk forbindelse og farmasøytisk anvendelse derav
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
DK1948695T3 (da) Immunogene sammensætninger og fremgangsmåder til andvendelse
DK3524657T3 (da) Sammensætninger omfattende hfc-1234yf og hfc-32
DK1670769T3 (da) Benzimidazol-derivater, sammensætninger indeholdende disse, fremstilling deraf og anvendelser deraf
DK1901731T3 (da) Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK1611115T3 (da) Benzothiazolderivatforbindelser, sammensætninger og anvendelser deraf